Evidence

The science behind dose timing

Oxford-validated chronodosing is trial-evidenced but still untranslated in everyday practice — DIOS closes that gap

Tier 1 — Foundational authority

2022

Life Time: The New Science of the Body Clock

Foster, R.

Sleep and Circadian Neuroscience Institute, University of Oxford

Penguin. Sunday Times bestseller. Chapter 10: "When to Take Drugs" — dedicated chapter establishing chronodosing as clinically significant across stroke, cardiovascular disease, and metabolic conditions.

Confirms for DIOS: Chronodosing is Oxford-validated mainstream science, not an emerging fringe position.

2024DOI: 10.1016/j.eclinm.2024.102633

Effect of timed dosing of usual antihypertensives according to patient chronotype on cardiovascular outcomes: the Chronotype sub-study cohort of the TIME study

Pigazzani, F. et al.

University of Dundee / University of Warwick

eClinicalMedicine.

Confirms for DIOS: Chronotype-informed antihypertensive dosing influences cardiovascular outcomes. Closest clinical trial to DIOS's core antihypertensive module. Used a questionnaire — DIOS replaces this with continuous wearable-derived MSFsc.

Tier 2 — Drug-specific evidence

2020

Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial

Hermida, R.C. et al.

European Heart Journal. 41(48): 4565–4576.

Hygia reproducibility questions exist — present as supporting evidence alongside TIME study, not as standalone proof.

Confirms for DIOS: Bedtime antihypertensive dosing reduces cardiovascular events.

2016

Dosing-Time Makes the Poison: Circadian Regulation and Pharmacotherapy

Dallmann, R., Okyar, A., Lévi, F.

Trends in Molecular Medicine. 22(5): 430–445.

Confirms for DIOS: Circadian regulation of drug metabolism affects efficacy and toxicity across drug classes.

2008

Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes

Hermida, R.C. et al.

Diabetes Care. 31(12): 2313–2318.

Confirms for DIOS: Timing of antihypertensive treatment affects cardiovascular risk specifically in diabetic patients.

2003

Taking simvastatin in the morning compared with in the evening: randomised controlled trial

Wallace, A. et al.

BMJ. 327(7418): 788. (Evening simvastatin evidence base; Preitner et al., 2002.)

Confirms for DIOS: Simvastatin is consistently more effective when taken in the evening. Strongest and most actionable chronodosing evidence.

2007

Chronobiology, drug delivery, and chronotherapeutics

Smolensky, M.H., Peppas, N.A.

Advanced Drug Delivery Reviews. 59(9–10): 828–851.

Confirms for DIOS: Chronotherapy framework for anti-inflammatory and corticosteroid dosing, including pre-dawn inflammatory peak mechanism.

Tier 3 — Population and equity evidence

2007

Epidemiology of the human circadian clock

Roenneberg, T. et al.

Sleep Medicine Reviews. 11(6): 429–438.

Derived primarily from Central European populations — the demographic gap DIOS corrects for.

Confirms for DIOS: MSFsc (mid-sleep on free days corrected for sleep debt) as the validated chronotype metric.

2022

Timing of Administration: For Commonly-Prescribed Medicines in Australia

Amiama-Roig, A. et al.

Pharmaceutics. 8(1): 13. PMC4932476.

Confirms for DIOS: In 56% of studies reviewed, therapeutic effect varied with time of administration. Information provision to patients and health professionals about optimal timing lags behind evidence.

2025

Stuck in time: The slow march of circadian medicine and how to speed it up

Cajochen, C. et al.

Journal of Sleep Research.

Confirms for DIOS: Clinicians do not routinely apply chronobiological approaches — the clinical translation gap DIOS exists to close.

Why standard chronotherapy guidelines aren't enough

Statement of design intent — not a scientific claim.

Every major chronotherapy trial — Hygia, MAPEC, TIME, the Roenneberg chronotype normative dataset — was conducted on predominantly Northern and Southern European populations. The MSFsc norms, the dip timing thresholds, the recommended dosing windows: all calibrated to a demographic that represents a fraction of the patients GPs see in Auckland, London, or Melbourne.

DIOS is the first platform to correct for this. Skin tone-adjusted light entrainment, location-specific photoperiod, and wearable-derived chronotype mean that a Māori patient in Auckland in June and a South Asian patient in Birmingham in December receive timing recommendations calibrated to their actual body clock — not a German or Spanish population average.

The researchers who established chronodosing as clinical science

Chronodosing is the conclusion of decades of circadian science — DIOS is the clinical tool they argued should exist

Prof. Russell Foster FRS

University of Oxford

Director, Sleep and Circadian Neuroscience Institute (SCNi) / Head, Nuffield Laboratory of Ophthalmology

Key work · Life Time (Penguin, 2022) — Sunday Times bestseller. Chapter 10: "When to Take Drugs." Discovered photosensitive retinal ganglion cells (pRGCs) — the biological mechanism underlying light-driven circadian entrainment.

→ The leading UK authority on circadian neuroscience. Life Time establishes chronodosing as mainstream Oxford science and argues directly for the clinical tool DIOS has built.

Prof. Roberto Manfredini

University of Ferrara, Italy

Chronobiologist, cardiovascular chronotherapy researcher

Key work · Co-author, TIME Chronotype sub-study (eClinicalMedicine, 2024). Extensive publication record on circadian cardiovascular risk.

→ Core investigator on the closest clinical trial to DIOS's antihypertensive module — chronotype-informed dosing of antihypertensives and cardiovascular outcomes.

Prof. Filippo Pigazzani

University of Dundee (MEMO Research)

Lead author, TIME Chronotype sub-study

Key work · Pigazzani et al. (2024). "Effect of timed dosing of usual antihypertensives according to patient chronotype on cardiovascular outcomes." eClinicalMedicine. DOI: 10.1016/j.eclinm.2024.102633

→ Used a questionnaire to assess chronotype. DIOS replaces the questionnaire with continuous wearable-derived MSFsc — the next step this trial pointed towards.

Prof. Francis Lévi

Warwick Medical School / INSERM Paris

Pioneer of cancer chronotherapy, founder of the Warwick Cancer Chronotherapy Unit

Key work · inCASA European Project — first home-based multidrug chronotherapy delivery platform for metastatic cancer patients. Over 30 years of clinical chronotherapy trials.

→ Established the clinical feasibility of wearable-monitored chronotherapy delivery at home. DIOS extends this model from oncology into primary care.

Prof. Till Roenneberg

Ludwig Maximilian University of Munich

Chronobiologist, developer of the Munich Chronotype Questionnaire (MCTQ)

Key work · Roenneberg et al. (2007). "Epidemiology of the human circadian clock." Sleep Medicine Reviews. 11(6): 429–438. Coined "social jet lag." Developed MSFsc as the validated chronotype metric.

→ DIOS uses MSFsc — Roenneberg's validated metric — derived continuously from wearable data rather than a one-time questionnaire. His normative dataset was European; DIOS corrects for non-European populations.

Prof. Ramon Hermida

University of Vigo, Spain

Lead investigator, Hygia Chronotherapy Trial and MAPEC study

Key work · Hermida et al. (2020). "Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial." European Heart Journal. 41(48): 4565–4576.

→ Established bedtime antihypertensive dosing as superior for cardiovascular outcomes — the core evidence for DIOS's non-dipper detection module. Note: reproducibility questions exist around Hygia; DIOS cites alongside the TIME study for balance.

Prof. Michael Smolensky

University of Texas, Houston

Chronobiologist, founding figure of clinical chronotherapy

Key work · Smolensky, M.H., Peppas, N.A. (2007). "Chronobiology, drug delivery, and chronotherapeutics." Advanced Drug Delivery Reviews. 59(9–10): 828–851.

→ Established the chronotherapy framework for anti-inflammatory and corticosteroid dosing — the evidence base for DIOS's prednisolone and NSAID module.

Prof. Christian Cajochen

University of Basel, Centre for Chronobiology

Chronobiologist, circadian medicine translation researcher

Key work · Cajochen et al. (2025). "Stuck in time: The slow march of circadian medicine and how to speed it up." Journal of Sleep Research.

→ Documented precisely the clinical translation gap DIOS exists to close — chronobiological approaches exist but clinicians do not routinely apply them. DIOS is the workflow tool that removes that friction.

See how DIOS implements chronodosing in your practice →

The evidence

The circadian disruption spectrum runs from mild jetlag to chronic pathology

DIOS intervenes where shift-worker populations sit on the curve from mild jetlag to chronic disease

Mild / AcuteSevere / Chronic

Social jetlag from misaligned social and biological clocks

Metabolic strain from sustained circadian drift

Elevated cancer risk in long-term shift cohorts

Neural decline linked to broken sleep architecture

Mild acute disruption detected at population scale

Social jetlag and shift-work disorder sit at the earliest point on the curve

Behavioural misalignment between social and biological clocks is the first signal DIOS can detect before pathology develops

Intermediate metabolic disruption before formal diagnosis

Metabolic and cardiovascular strain follows months of sustained clock drift

Population-level insulin and vascular dysfunction often precedes a formal diabetes or heart disease diagnosis by years

Severe systemic risk in chronically misaligned cohorts

Oncological burden rises when DNA repair cycles lose circadian control

Night-shift populations show measurably higher cancer incidence when clock-driven cell repair fails

Chronic neurological decline at the far end of the spectrum

Dementia risk grows when glymphatic clearance loses nightly circadian drive

Broken sleep architecture stops the brain clearing toxic waste and drift velocity tracks neurodegenerative onset in cohorts

DIOS catches circadian disruption at the behavioural stage — before metabolic, cancer, or neurological pathology — and informs the prescribing decision without prescribing or dosing

PMC reference search

← Back to homepage